Prospective Observational Pilot-study for the Evaluation of the Nephro- an Neurotoxicity in the Anti-infectious Therapy With Inhalative Colistin Therapy for Patients With Ventilator-associated Pneumonia (VAP)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

9 participants

Study Classification

OBSERVATIONAL

Study Start Date

2013-09-30

Study Completion Date

2015-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Multi-Drug resistant pathogens (MDR) are reported worldwide with increasing incidence, especially in intensive care settings.

One of the drugs which are effective against MDRs, is colistin (polymyxin E). This agent has been reintroduced in response to the increase of MDR pathogens and might be used more often in the future. Data on safety regarding the most important side effects are not sufficiently available. l This study evaluates the toxicity in patients who receive aerosolized colistin.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Nebulized and Intravenous Colistin in Ventilator Associated-pneumonia

NCT02906722

Ventilator-associated Pneumonia

TERMINATED PHASE3

Effect of Aerosolised Colistin in Ventilator Associated Pneumonia

NCT02683603

Pneumonia, Ventilator-Associated

COMPLETED PHASE4

Nebulized Colistin for Gram Negative VAP Prevention.

NCT04208945

Pneumonia, Ventilator-associated Gram-Negative Pneumonia

UNKNOWN NA

Population Pharmacokinetic-pharmacodynamic (PK-PD) Study of 9 Broad-Spectrum Anti-infective Agents in the Cerebro Spinal Fluid (CSF) of Brain Injured Patients With an External Ventricular Drainage (EVD).

NCT03481569

Infection

COMPLETED PHASE1

Colistin Methanesulfonate Sodium Inhalation for Prophylaxis of Ventilator-Associated Pneumonia (CIVAP): A Prospective, Multicentre, Double-Blind, Randomized, Placebo-Controlled Trial

NCT06834971

Ventilator-Associated Pneumonia (VAP)

RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

There is growing evidence that patients in the ICU setting have a special risk profile for consecutive colonization and possible infection due to MDR pathogens.

One therapy option is the use of inhalative colistin, as this agent has been demonstrated to be effective against these pathogens. Data on pharmacodynamics or - kinetics are transferred from older studies or from other patient populations. For patients with pulmonary colonization or infection due to an MDR pathogen the systemic resorption of the drug is not known, consequently systemic side effects including kidney or neural damage are not predictable.

This study focus on patients with inhalative colistin therapy and uses therapeutic drug monitoring to determine the rate of systemic resorption of colistin. For the evaluation of neurotoxicity function of peripheral nerves (neve conduction velocity) and of the eighth cranial nerve is monitored. Nephrotoxicity is estimated by creatinine level (-clearance) and the RIFLE criteria.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Infection Resistant to Multiple Drugs

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Colistin inhalative

Adult ICU patients with

* invasive ventilation with assumed or assured bacteria with an elevated resistance pattern found in a tracheal or bronchial secretion with or without clinical signs of infection
* indicated colistin co-therapy or eradication-attempt with inhalative colistin (β-Lactam) therapy according to the standard operation procedure (SOP) of the hospital

Patients included into the study group receive additional TDM, Monitoring of Neuro-and Nephropathology

TDM, Monitoring of Neuro-and Nephropathology

Intervention Type OTHER

Therapeutic drug monitoring of serum levels and Monitoring of Neuro- and Nephropathology

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

TDM, Monitoring of Neuro-and Nephropathology

Therapeutic drug monitoring of serum levels and Monitoring of Neuro- and Nephropathology

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* invasive ventilated patients (male and female) with assumed or assured bacteria with an elevated resistance pattern found in a tracheal or bronchial secretion with or without clinical signs of infection
* indicated colistin co-therapy or eradication-attempt with inhalative colistin (β-Lactam) therapy according to the standard operation procedure (SOP) of the hospital

Exclusion Criteria

* Consent of the patient or of the patient´s legal representative can´t be obtained soon
* Age \< 18 years
* Included within another, prospective clinical antibiotics-study
* Hypersensitivity to colistin or polymyxin B
* Patients with cystic fibrosis
* Present letter of attorney or patient´s provision, which precludes a priori the participation in studies
* Missing consent for storage of pseudonymised data in context of the study
* The patient is in an institution due to a court injunction or administrative order

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No